ReShape Lifesciences Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
HIND$1.54-3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||
| · · 2023 · · 2022 | ||||||
| Cash flows from operating activities: · · · · | ||||||
| Net loss | | $(11,387) | | $(46,214) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | |
| Depreciation expense | | 121 | | 330 | ||
| Amortization of intangible assets | | | 33 | | | 1,823 |
| Impairment of long-lived assets | | | 777 | | | 18,744 |
| (Gain) loss on disposal of assets, net | | | (33) | | | 529 |
| Stock-based compensation | | | 766 | | | 2,087 |
| Bad debt expense | | | 395 | | | (43) |
| Provision for inventory excess and obsolescence | | | 335 | | | 579 |
| Deferred income tax | | | 28 | | | (423) |
| Gain on changes in fair value of liability warrants | | | (3,878) | | | — |
| Other noncash items | | | 17 | | | (23) |
| Change in operating assets and liabilities: | | | | | ||
| Accounts and other receivables | | 125 | | 678 | ||
| Inventory | | (465) | | (1,187) | ||
| Prepaid expenses and other current assets | | (172) | | 1,141 | ||
| Accounts payable and accrued liabilities | | | (3,457) | | | 448 |
| Warranty liability | | (182) | | (371) | ||
| Other | | 17 | | — | ||
| Net cash used in operating activities | | | (16,960) | | | (21,902) |
| Cash flows from investing activities: | | | | | | |
| Capital expenditures | | | (43) | | | (131) |
| Proceeds from sale of capital assets | | | 33 | | | 39 |
| Cash used in investing activities: | | | (10) | | | (92) |
| Cash flows from financing activities: | | | | | | |
| Proceeds from sale and issuance of securities, net | | | 13,438 | | | 639 |
| Proceeds from warrants exercised | | | 4,136 | | | 2,491 |
| Net cash provided by financing activities | | | 17,574 | | | 3,130 |
| Effect of currency exchange rate changes on cash and cash equivalents | | — | | 4 | ||
| Net change in cash, cash equivalents and restricted cash | | 604 | | (18,860) | ||
| Cash, cash equivalents and restricted cash at beginning of period | | | 3,955 | | | 22,815 |
| Cash, cash equivalents and restricted cash at end of period | | $4,559 | | $3,955 | ||
| Supplemental disclosure: | | | | | | |
| Cash paid for income taxes | | $10 | | $5 | ||
| Cash paid for interest | | | — | | | — |
| Noncash investing and financing activities: | | | | | | |
| Capital expenditures accruals | | $— | | $6 | ||
ReShape Lifesciences Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.